Ann: Appendix 4D and Half Year Financial Report, page-40

Upcoming Milestones:
• Commence next phase of in-human trials
• Continue to work toward seeking necessary regulatory approvals
• Follow up first-in-human patient data•

In Q1, the Company welcomed Australian cardiologist Dr Karl Poon to its global Medical Advisory Board. On 12 July 2022, the Company welcomed Dr Martin Leon, who is globally recognized as an early pioneer in the development of minimally invasive approaches to treating coronary and structural heart disease. Both Doctors will help accelerate the Company’s progress in both product development and clinical science to bring validation for our novel DurAVRTM Transcatheter Heart Valve System for patients with severe aortic stenosis.

IMO it is not unreasonable to expect some details soon, including a possible FDA pre-submission feedback.